Exclusive speaker interview with SCHOTT Pharmaceutical Systems released for Pre-Filled Syringes East Coast 2019

SMi Group8 - 9 April 2019, Boston, USA.
The 6th Annual Pre-Filled Syringes East Coast conference is returning to Boston, USA. The two-day event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.

In the run up to the conference, SMi Group caught up with Patrick Gallagher, Business Development Manager, SCHOTT Pharmaceutical Systems, to discuss his upcoming presentation, and his thoughts on the current challenges and opportunities in the pre-filled syringes field.

A snapshot of Patrick Gallagher's interview

Q: The Pre-Filled Syringes market has matured greatly over recent years, what key differences have you noticed in the last year regarding significant developments? A: "In recent years, we have seen quite a bit of interest from pharmaceutical companies to differentiate through delivery device, whether through lifecycle management of a biologic drug into a more complex device or by converting a legacy drug from vial to pre-filled syringe. PFS and cartridge-based primary containers can improve patient safety through less dose preparation and greater ease of use, as well as facilitate the transition of drug administration from a hospital to homecare setting, thus improving patient outcomes."

Q: What do you see as the greatest challenge for you to overcome personally in the pre-filled syringes field at the moment? A: "As an industry, we are still in the early stages of developing connected health solutions and while we are starting to generate significant data it will take some time to best realize how to use this data. Pharma and Medtech companies will need to continue to educate key healthcare stakeholders that device-generated data can improve patient outcomes and drive down healthcare costs."

The full speaker interview and more content including the latest brochure, past attendees list, and other exclusive speaker interviews can be found on the DOWNLOADS section on the website at http://www.pfsamericas.com/pr7

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...